A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
Public ClinicalTrials.gov record NCT04486352. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase IB/II Multi-Cohort Study of Targeted Agents and/or Immunotherapy With Atezolizumab for Patients With Recurrent or Persistent Endometrial Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase IB/II multi-cohort study designed to evaluate the efficacy and safety of targeted agents with or without cancer immune checkpoint therapy with atezolizumab in participant with recurrent and/or persistent endometrial cancer. The main protocol provides a platform for genomic screening with homogeneous basic eligibility criteria in order to direct study participants into biomarker-matched study cohorts consisting of testing targeted agents.
Study identification
- NCT ID
- NCT04486352
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 148 participants
Conditions and interventions
Conditions
Interventions
- Atezolizumab - 28 Day Cycle Drug
- Bevacizumab Drug
- Ipatasertib Drug
- Talazoparib Drug
- Trastuzumab emtansine Drug
- Tiragolumab Drug
- Atezolizumab - 21 Day Cycle Drug
- Inavolisib Drug
- Letrozole Drug
- Giredestrant Drug
- Abemaciclib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 19, 2021
- Primary completion
- Sep 30, 2026
- Completion
- Sep 30, 2027
- Last update posted
- Mar 31, 2026
2021 – 2027
United States locations
- U.S. sites
- 21
- U.S. states
- 18
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope Comprehensive Cancer Center | Duarte | California | 91010 | Active, not recruiting |
| UCSF Helen Diller Family Comprehensive Cancer Center | San Francisco | California | 94143 | Active, not recruiting |
| Medstar Georgetown Cancer Institute | Washington D.C. | District of Columbia | 20007 | Active, not recruiting |
| Mount Sinai Comprehensive Cancer Center | Miami Beach | Florida | 33140 | Active, not recruiting |
| University of Chicago | Chicago | Illinois | 60637 | Active, not recruiting |
| University of Kansas Cancer Center | Westwood | Kansas | 66205 | Active, not recruiting |
| Maine Medical Center | Scarborough | Maine | 04074 | Active, not recruiting |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02125 | Active, not recruiting |
| University of Minnesota | Minneapolis | Minnesota | 55455 | Active, not recruiting |
| Washington University School of Medicine Siteman Cancer Center | St Louis | Missouri | 63110 | Withdrawn |
| Nebraska Methodist Hospital | Omaha | Nebraska | 68114 | Active, not recruiting |
| Englewood Health | Englewood | New Jersey | 07631 | Active, not recruiting |
| Atlantic Health Systems/Morristown Medical Center | Morristown | New Jersey | 07960 | Active, not recruiting |
| Roswell Park | Buffalo | New York | 14263 | Active, not recruiting |
| Weill Cornell Medicine | New York | New York | 10065 | Active, not recruiting |
| Duke University Cancer Center | Durham | North Carolina | 27710 | Active, not recruiting |
| University of Oklahoma Health Stephenson Cancer Center | Oklahoma City | Oklahoma | 73104 | Recruiting |
| Providence Portland Cancer Institute | Portland | Oregon | 97213 | Active, not recruiting |
| University of Pittsburgh Medical Center | Pittsburgh | Pennsylvania | 15261 | Active, not recruiting |
| Lifespan - Rhode Island Hospital | Providence | Rhode Island | 02903 | Active, not recruiting |
| Baptist Memorial Hospital | Memphis | Tennessee | 38120 | Withdrawn |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04486352, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 31, 2026 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04486352 live on ClinicalTrials.gov.